首页 > 最新文献

Tanaffos最新文献

英文 中文
Factors Affecting the Medical Coding Errors of COVID-19 Hospital Records: A Cross-Sectional Study in East Iran. 影响2019冠状病毒病案医疗编码错误的因素:伊朗东部地区的横断面研究
Q3 Medicine Pub Date : 2024-02-01
Ali Garavand, Erfan Esmaeeli, Fatemeh Bahador, Azam Sabahi

Background: During the COVID-19 pandemic, disease coding significantly influenced national and international strategies for prevention, treatment, and control. This study aimed to assess the factors influencing COVID-19 records' coding errors in teaching hospitals in South Khorasan province.

Materials and methods: In 2022, researchers conducted a cross-sectional study in South Khorasan Province, Iran. Data was gathered using a self-developed questionnaire distributed among medical coders in all hospitals. Descriptive statistics were employed in the data analysis using SPSS version 19.

Results: The study's results showed that non-observance of diagnostic principles by physicians (66 out of 92), a lack of specialized medical coding specialists (52 out of 92), and the use of ambiguous and non-standard abbreviations (51 out of 92) were the most significant factors affecting COVID-19 coding errors. Among the three main factors affecting COVID-19 records' coding errors, factors related to the medical coder (47.66 out of 92), factors related to healthcare providers (29.8 out of 92), and organizational and environmental factors (21.4 out of 92) were the most significant.

Conclusion: This study revealed that multiple factors contribute to coding errors in COVID-19 records, with the most critical being physicians' non-adherence to diagnostic principles, the shortage of medical coding specialists, the use of unclear and non-standard abbreviations, and the absence of COVID-19 coding continuing education. Therefore, we recommend conducting workshops on diagnosis and coding for medical coders, particularly emphasizing the precise coding of COVID-19 records.

背景:在2019冠状病毒病大流行期间,疾病编码对国家和国际预防、治疗和控制战略产生了重大影响。本研究旨在评估南呼罗珊省教学医院COVID-19记录编码错误的影响因素。材料和方法:2022年,研究人员在伊朗南呼罗珊省进行了一项横断面研究。采用自行编制的问卷收集数据,在所有医院的医疗编码人员中分发。数据分析采用描述性统计,使用SPSS 19。结果:研究结果显示,医生不遵守诊断原则(92人中有66人)、缺乏专业的医疗编码专家(92人中有52人)、使用歧义和不规范的缩写(92人中有51人)是影响COVID-19编码错误的最重要因素。在影响COVID-19记录编码错误的三个主要因素中,与医疗编码员相关的因素(47.66 / 92)、与医疗服务提供者相关的因素(29.8 / 92)、组织和环境因素(21.4 / 92)最为显著。结论:本研究揭示了导致COVID-19记录编码错误的多重因素,其中最关键的是医生不遵守诊断原则、缺乏医学编码专家、使用不明确和不规范的缩写以及缺乏COVID-19编码继续教育。因此,我们建议为医疗编码人员举办诊断和编码研讨会,特别强调对COVID-19记录进行精确编码。
{"title":"Factors Affecting the Medical Coding Errors of COVID-19 Hospital Records: A Cross-Sectional Study in East Iran.","authors":"Ali Garavand, Erfan Esmaeeli, Fatemeh Bahador, Azam Sabahi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>During the COVID-19 pandemic, disease coding significantly influenced national and international strategies for prevention, treatment, and control. This study aimed to assess the factors influencing COVID-19 records' coding errors in teaching hospitals in South Khorasan province.</p><p><strong>Materials and methods: </strong>In 2022, researchers conducted a cross-sectional study in South Khorasan Province, Iran. Data was gathered using a self-developed questionnaire distributed among medical coders in all hospitals. Descriptive statistics were employed in the data analysis using SPSS version 19.</p><p><strong>Results: </strong>The study's results showed that non-observance of diagnostic principles by physicians (66 out of 92), a lack of specialized medical coding specialists (52 out of 92), and the use of ambiguous and non-standard abbreviations (51 out of 92) were the most significant factors affecting COVID-19 coding errors. Among the three main factors affecting COVID-19 records' coding errors, factors related to the medical coder (47.66 out of 92), factors related to healthcare providers (29.8 out of 92), and organizational and environmental factors (21.4 out of 92) were the most significant.</p><p><strong>Conclusion: </strong>This study revealed that multiple factors contribute to coding errors in COVID-19 records, with the most critical being physicians' non-adherence to diagnostic principles, the shortage of medical coding specialists, the use of unclear and non-standard abbreviations, and the absence of COVID-19 coding continuing education. Therefore, we recommend conducting workshops on diagnosis and coding for medical coders, particularly emphasizing the precise coding of COVID-19 records.</p>","PeriodicalId":22247,"journal":{"name":"Tanaffos","volume":"23 2","pages":"189-197"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medication Errors and Its Relationship with Patient Safety Culture: Evidence from Nurses' Viewpoint During COVID-19 Pandemic. 用药差错及其与患者安全文化的关系:来自COVID-19大流行期间护士视角的证据
Q3 Medicine Pub Date : 2024-02-01
Peivand Bastani, Eshagh Barfar, Ali Reza Yusefi, Ehsan Movahed, Neda Dastyar, Sisira Edirippulige

Background: Medication errors can lead to damage to patients with various disabilities or death. This study aims to identify factors affecting the incidence of medication error and its association with patient safety culture from the nurse's perspective during the COVID-19 pandemic.

Materials and methods: This cross-sectional study was conducted among 340 employed in the hospitals affiliated with Shiraz University of Medical Sciences in 2021. Data were collected by applying a questionnaire for medication error and the standard questionnaire of the Hospital Survey on Patient Safety Culture. Descriptive statistics, the independent t-test, ANOVA, and Pearson correlation were applied using SPSS software version 23.

Results: The main reasons for medication errors were fatigue due to the workload (3.13±1.16 out of 5), method of supervision in the hospital units (3.06±0.98 out of 5), and massive pile-up of duties (3.00±1.19 out of 5). Other results indicated a significant negative association between factors affecting medication error and patient safety culture (r=-0.574, p=0.002). A significant correlation was observed among factors affecting medication error and patient safety culture with demographic determinants of age and years of working experience (p<0.05). Significant differences were also observed among the two main studied variables, the number of monthly work shifts, and the number of patients (p<0.05).

Conclusion: Applying strategies for the reduction of physical fatigue and mental exhaustion along with balancing work shifts and managing the accumulative duties and massive tasks can help decrease the rates of medication errors.

背景:用药错误可导致各种残疾患者的损害或死亡。本研究旨在从护士角度探讨新冠肺炎大流行期间影响用药差错发生率的因素及其与患者安全文化的关系。材料与方法:本横断面研究以设拉子医科大学附属医院2021年340名就诊者为研究对象。采用用药差错调查问卷和《医院患者安全文化调查》标准问卷收集数据。采用SPSS软件23版进行描述性统计、独立t检验、方差分析和Pearson相关分析。结果:造成用药差错的主要原因是工作量疲劳(3.13±1.16 / 5)、医院单位监管方式(3.06±0.98 / 5)和大量任务堆积(3.00±1.19 / 5),其他影响用药差错的因素与患者安全培养呈显著负相关(r=-0.574, p=0.002)。影响用药错误和患者安全文化的因素与年龄和工作年限的人口统计学决定因素之间存在显著的相关性。结论:采用减少身体疲劳和精神疲惫的策略,平衡工作班次,管理累积的职责和大量的任务,有助于降低用药错误的发生率。
{"title":"Medication Errors and Its Relationship with Patient Safety Culture: Evidence from Nurses' Viewpoint During COVID-19 Pandemic.","authors":"Peivand Bastani, Eshagh Barfar, Ali Reza Yusefi, Ehsan Movahed, Neda Dastyar, Sisira Edirippulige","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Medication errors can lead to damage to patients with various disabilities or death. This study aims to identify factors affecting the incidence of medication error and its association with patient safety culture from the nurse's perspective during the COVID-19 pandemic.</p><p><strong>Materials and methods: </strong>This cross-sectional study was conducted among 340 employed in the hospitals affiliated with Shiraz University of Medical Sciences in 2021. Data were collected by applying a questionnaire for medication error and the standard questionnaire of the Hospital Survey on Patient Safety Culture. Descriptive statistics, the independent t-test, ANOVA, and Pearson correlation were applied using SPSS software version 23.</p><p><strong>Results: </strong>The main reasons for medication errors were fatigue due to the workload (3.13±1.16 out of 5), method of supervision in the hospital units (3.06±0.98 out of 5), and massive pile-up of duties (3.00±1.19 out of 5). Other results indicated a significant negative association between factors affecting medication error and patient safety culture (r=-0.574, p=0.002). A significant correlation was observed among factors affecting medication error and patient safety culture with demographic determinants of age and years of working experience (p<0.05). Significant differences were also observed among the two main studied variables, the number of monthly work shifts, and the number of patients (p<0.05).</p><p><strong>Conclusion: </strong>Applying strategies for the reduction of physical fatigue and mental exhaustion along with balancing work shifts and managing the accumulative duties and massive tasks can help decrease the rates of medication errors.</p>","PeriodicalId":22247,"journal":{"name":"Tanaffos","volume":"23 2","pages":"198-208"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is It Unnecessary to Assess Tumor Stroma-Infiltrating Lymphocytes in Localized Lung Adenocarcinomas? 局限性肺腺癌是否需要评估肿瘤间质浸润淋巴细胞?
Q3 Medicine Pub Date : 2024-02-01
Mona Mlika, Abir Rais, Omar El Mnif, Chokri Haddouchi, Mehdi Abdennadher, Rahma Ayadi, Emna Braham, Olfa Ismail, Adel Marghli, Faouzi Mezni

Background: During the last decade, more attention was paid to the tumor cell microenvironment, especially to tumor stroma-infiltrating lymphocytes (TILs). This study aimed to assess the prognostic impact of different TILs subpopulations and PD-L1 positive tumor cells in localized lung adenocarcinomas.

Materials and methods: We conducted a retrospective descriptive study, which included localized adenocarcinomas diagnosed in the department of pathology and resected in the Thoracic Surgery Department of the same hospital between 2015 and 2020. TILs were analyzed using the immunohistochemical method for Fox-P3, CD4, CD8, CD20, and CD3. Besides, the PD-L1 antibody was used to assess tumor cell expression. Intra-tumoral and stromal labeled lymphocytes were quantified by manual counting at high magnification (X400). Fox-P3+/CD8+, Fox-P3+/CD4+, FoxP3+/PD-L1+, and CD8+/CD4+ ratios were subsequently calculated. The prognostic value of TILs was assessed with respect to overall survival (OS) and recurrence free survival (ReFS).

Results: A total of 44 localized adenocarcinomas were included. In the univariate analysis, the prognostic factors influencing OS included gender, adenocarcinoma subtype, Tumor-Infiltrating Lymphocyte (TIL) score, TIL grade, PD-L1 expression, PD-L1 grade, tumor immunity in the microenvironment, and the expressions of various immune markers: CD3, CD4, CD8, CD20, and FoxP3. The analysis also considered the FoxP3 ratio, FIL score, and different ratios involving immune markers, such as CD8/CD4 ratio, FoxP3/CD8 ratio, FoxP3/CD4 ratio, and FoxP3/PD-L1 ratio. The prognostic factors influencing the ReFS consisted of gender, the adenocarcinoma subtype, TIL score, TIL grade, PD-L1, PD-L1 grade, TIM, CD8 expression, CD20 expression, FIL score, Fox-P3/CD8 ratio, Fox-P3/CD4 ratio, and Fox-P3/PD-L1 ratio. Multivariate analysis revealed no independent predictive factors of OS or ReFS.

Conclusion: Despite the limitations of this study, the results highlighted that TILs may not represent an independent prognostic factor in localized adenocarcinomas and don't play a major role in comparison to the tumor stage.

背景:近十年来,肿瘤细胞微环境,特别是肿瘤基质浸润淋巴细胞(til)的研究越来越受到重视。本研究旨在评估不同TILs亚群和PD-L1阳性肿瘤细胞在局限性肺腺癌中的预后影响。材料与方法:我们对2015 - 2020年同一医院胸外科病理诊断并切除的局限性腺癌进行回顾性描述性研究。采用免疫组织化学方法分析TILs中Fox-P3、CD4、CD8、CD20和CD3的表达。同时用PD-L1抗体检测肿瘤细胞表达。采用人工高倍显微镜(X400)对肿瘤内和基质标记淋巴细胞进行计数。计算Fox-P3+/CD8+、Fox-P3+/CD4+、FoxP3+/PD-L1+和CD8+/CD4+比值。根据总生存期(OS)和无复发生存期(ReFS)评估TILs的预后价值。结果:共纳入44例局部腺癌。在单因素分析中,影响OS的预后因素包括性别、腺癌亚型、肿瘤浸润淋巴细胞(TIL)评分、TIL分级、PD-L1表达、PD-L1分级、肿瘤微环境免疫以及各种免疫标志物CD3、CD4、CD8、CD20和FoxP3的表达。分析还考虑了FoxP3比值、FIL评分以及涉及免疫标志物的不同比值,如CD8/CD4比值、FoxP3/CD8比值、FoxP3/CD4比值、FoxP3/PD-L1比值。影响ReFS预后的因素包括性别、腺癌亚型、TIL评分、TIL分级、PD-L1、PD-L1分级、TIM、CD8表达、CD20表达、FIL评分、Fox-P3/CD8比值、Fox-P3/CD4比值、Fox-P3/PD-L1比值。多因素分析未发现OS或ReFS的独立预测因素。结论:尽管本研究存在局限性,但结果强调,TILs可能不是局部腺癌的独立预后因素,与肿瘤分期相比,TILs并不起主要作用。
{"title":"Is It Unnecessary to Assess Tumor Stroma-Infiltrating Lymphocytes in Localized Lung Adenocarcinomas?","authors":"Mona Mlika, Abir Rais, Omar El Mnif, Chokri Haddouchi, Mehdi Abdennadher, Rahma Ayadi, Emna Braham, Olfa Ismail, Adel Marghli, Faouzi Mezni","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>During the last decade, more attention was paid to the tumor cell microenvironment, especially to tumor stroma-infiltrating lymphocytes (TILs). This study aimed to assess the prognostic impact of different TILs subpopulations and PD-L1 positive tumor cells in localized lung adenocarcinomas.</p><p><strong>Materials and methods: </strong>We conducted a retrospective descriptive study, which included localized adenocarcinomas diagnosed in the department of pathology and resected in the Thoracic Surgery Department of the same hospital between 2015 and 2020. TILs were analyzed using the immunohistochemical method for Fox-P3, CD4, CD8, CD20, and CD3. Besides, the PD-L1 antibody was used to assess tumor cell expression. Intra-tumoral and stromal labeled lymphocytes were quantified by manual counting at high magnification (X400). Fox-P3+/CD8+, Fox-P3+/CD4+, FoxP3+/PD-L1+, and CD8+/CD4+ ratios were subsequently calculated. The prognostic value of TILs was assessed with respect to overall survival (OS) and recurrence free survival (ReFS).</p><p><strong>Results: </strong>A total of 44 localized adenocarcinomas were included. In the univariate analysis, the prognostic factors influencing OS included gender, adenocarcinoma subtype, Tumor-Infiltrating Lymphocyte (TIL) score, TIL grade, PD-L1 expression, PD-L1 grade, tumor immunity in the microenvironment, and the expressions of various immune markers: CD3, CD4, CD8, CD20, and FoxP3. The analysis also considered the FoxP3 ratio, FIL score, and different ratios involving immune markers, such as CD8/CD4 ratio, FoxP3/CD8 ratio, FoxP3/CD4 ratio, and FoxP3/PD-L1 ratio. The prognostic factors influencing the ReFS consisted of gender, the adenocarcinoma subtype, TIL score, TIL grade, PD-L1, PD-L1 grade, TIM, CD8 expression, CD20 expression, FIL score, Fox-P3/CD8 ratio, Fox-P3/CD4 ratio, and Fox-P3/PD-L1 ratio. Multivariate analysis revealed no independent predictive factors of OS or ReFS.</p><p><strong>Conclusion: </strong>Despite the limitations of this study, the results highlighted that TILs may not represent an independent prognostic factor in localized adenocarcinomas and don't play a major role in comparison to the tumor stage.</p>","PeriodicalId":22247,"journal":{"name":"Tanaffos","volume":"23 2","pages":"129-138"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-Flow Nasal Cannula versus Conventional Oxygen Therapy for Patients with Acute Respiratory Failure in the Emergency Department: A Randomized Controlled Trial. 急诊科急性呼吸衰竭患者高流量鼻插管与常规氧疗:一项随机对照试验
Q3 Medicine Pub Date : 2024-02-01
Mohammad Emami Ardestani, Mohammad Nasr-Esfahani, Fatemeh Sadat MirMohammad Sadeghi, Reza Azizkhani, Farhad Heydari

Background: To compare the efficacy of a high-flow nasal cannula (HFNC) versus conventional oxygen therapy (COT) in the treatment of patients admitted to the emergency department (ED) for acute respiratory failure (ARF).

Materials and methods: In this prospective randomized clinical trial, 66 patients aged 18 years or older who presented with ARF to the ED were enrolled and assigned into two equal groups to receive either COT or HFNC for 60 minutes. The primary outcome was the intubation rates. The secondary outcomes were the effect of intervention on oxygenation, ICU admission rate, and effect on physiologic variables.

Results: 33 patients were treated in each group. The main causes of ARF were chronic obstructive pulmonary disease (COPD), pneumonia, and asthma. The need for intubation was higher in COT than in HFNC (42.5% vs 12.1%, P = 0.004). Patients with HFNC had a higher dyspnea improvement than those treated with COT (93.9% vs 63.7%, P = 0.002). They also showed greater improvement in oxygen saturation (increase in SpO2 was 8.3% vs. -0.5, difference 8.8% (6.8 to 10.9)), and in respiratory rate (decrease 3.0 beats/min vs 0.2 beats/min, differences 2.8(0.8 to 4.6)). The ICU admission was higher in the COT group (51.5 vs 15.2, P=0.002).

Conclusion: HFNC reduced the need for intubation and ICU admission in the patients presenting to the ED with ARF compared with COT. In addition, HFNC was associated with a greater reduction in RR and improvement in SpO2 compared with COT.

背景:比较高流量鼻插管(HFNC)与常规氧疗(COT)治疗急诊科(ED)急性呼吸衰竭(ARF)患者的疗效。材料和方法:在这项前瞻性随机临床试验中,66名18岁及以上的急诊科ARF患者被纳入研究,并被分为两组,分别接受COT或HFNC治疗60分钟。主要观察指标为插管率。次要结局为干预对氧合的影响、ICU入院率及对生理指标的影响。结果:每组治疗33例。ARF的主要原因是慢性阻塞性肺疾病(COPD)、肺炎和哮喘。COT组插管需求高于HFNC组(42.5% vs 12.1%, P = 0.004)。HFNC患者的呼吸困难改善程度高于COT患者(93.9% vs 63.7%, P = 0.002)。他们也表现出更大的氧饱和度改善(SpO2增加8.3%对-0.5,差异8.8%(6.8到10.9)),呼吸频率(减少3.0次/分钟对0.2次/分钟,差异2.8(0.8到4.6))。COT组ICU住院率较高(51.5 vs 15.2, P=0.002)。结论:与COT相比,HFNC减少了急诊合并ARF患者插管和ICU住院的需要。此外,与COT相比,HFNC与更大程度的RR降低和SpO2改善相关。
{"title":"High-Flow Nasal Cannula versus Conventional Oxygen Therapy for Patients with Acute Respiratory Failure in the Emergency Department: A Randomized Controlled Trial.","authors":"Mohammad Emami Ardestani, Mohammad Nasr-Esfahani, Fatemeh Sadat MirMohammad Sadeghi, Reza Azizkhani, Farhad Heydari","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>To compare the efficacy of a high-flow nasal cannula (HFNC) versus conventional oxygen therapy (COT) in the treatment of patients admitted to the emergency department (ED) for acute respiratory failure (ARF).</p><p><strong>Materials and methods: </strong>In this prospective randomized clinical trial, 66 patients aged 18 years or older who presented with ARF to the ED were enrolled and assigned into two equal groups to receive either COT or HFNC for 60 minutes. The primary outcome was the intubation rates. The secondary outcomes were the effect of intervention on oxygenation, ICU admission rate, and effect on physiologic variables.</p><p><strong>Results: </strong>33 patients were treated in each group. The main causes of ARF were chronic obstructive pulmonary disease (COPD), pneumonia, and asthma. The need for intubation was higher in COT than in HFNC (42.5% vs 12.1%, P = 0.004). Patients with HFNC had a higher dyspnea improvement than those treated with COT (93.9% vs 63.7%, P = 0.002). They also showed greater improvement in oxygen saturation (increase in SpO<sub>2</sub> was 8.3% vs. -0.5, difference 8.8% (6.8 to 10.9)), and in respiratory rate (decrease 3.0 beats/min vs 0.2 beats/min, differences 2.8(0.8 to 4.6)). The ICU admission was higher in the COT group (51.5 vs 15.2, P=0.002).</p><p><strong>Conclusion: </strong>HFNC reduced the need for intubation and ICU admission in the patients presenting to the ED with ARF compared with COT. In addition, HFNC was associated with a greater reduction in RR and improvement in SpO<sub>2</sub> compared with COT.</p>","PeriodicalId":22247,"journal":{"name":"Tanaffos","volume":"23 2","pages":"156-162"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Variation of Immunoglobulin M and Immunoglobulin G Serum Levels in Seropositive COVID-19 Patients in Mazandaran, Iran: A Six-Month Investigation. 伊朗Mazandaran地区COVID-19血清阳性患者血清免疫球蛋白M和免疫球蛋白G水平变化:一项为期6个月的调查
Q3 Medicine Pub Date : 2024-02-01
Seyed Abbas Mousavi, Faezeh Sadat Movahedi, Fatemeh Safari Hajikalai, Jamshid Yazdani Charati, Abolghasem Ajami, Seyed Mohsen Soleimani, Zainab Bandalizadeh, Saeed Kaviani Charati

Background: Forecasting the longevity of patients' immune stability could be the most effective approach to preventing illnesses. This study investigates immunoglobulin M (IgM) serum longevity, immunoglobulin G (IgG), and corresponding risk factors in the first phase seropositive patients in Mazandaran, Iran.

Materials and methods: This descriptive cross-sectional study aimed to assess IgM and IgG serum levels in a cohort of 184 seropositive patients during six months. The data analysis involved various statistical methods including descriptive statistics, the chi-square test, independent and paired t-tests, and single and multivariate logistic regression.

Results: A total of 103 (56%) patients lacked the necessary antibodies, whereas 81 (44%) remained seropositive. According to the results of multivariable logistic regression, patients with a travel history, hospital admissions, and end-stage renal disease (ESRD) had 3.24 (P=0.04), 12.63 (P=0.018), and 9.79 (P=0.001) times higher chances of stable seropositivity, respectively. The average IgG and IgM serum levels fell by 4.5 and 3 units, respectively (P<0.001). In addition, serum levels of IgM and IgG increased by 12% and 12.5%, respectively, and dropped by 75.5% in both serums. There was no increase in either serum level for any of the patients.

Conclusion: The duration of immune serum stability in patients can significantly reduce disease mortality. The concurrent detection of IgM and IgG antibodies also assists in identifying the infectious stage.

背景:预测患者免疫稳定性的寿命可能是预防疾病的最有效方法。本研究调查了伊朗Mazandaran一期血清阳性患者的免疫球蛋白M (IgM)血清寿命、免疫球蛋白G (IgG)及其相关危险因素。材料和方法:本描述性横断面研究旨在评估184名血清阳性患者6个月内的IgM和IgG血清水平。数据分析采用多种统计方法,包括描述性统计、卡方检验、独立和配对t检验、单因素和多因素logistic回归。结果:共有103例(56%)患者缺乏必要的抗体,而81例(44%)患者仍呈血清阳性。多变量logistic回归结果显示,旅行史、住院史和终末期肾病(ESRD)患者稳定血清阳性的几率分别高出3.24倍(P=0.04)、12.63倍(P=0.018)和9.79倍(P=0.001)。血清IgG和IgM平均水平分别下降4.5和3个单位(p结论:患者免疫血清稳定时间的延长可显著降低疾病死亡率。同时检测IgM和IgG抗体也有助于确定感染阶段。
{"title":"Variation of Immunoglobulin M and Immunoglobulin G Serum Levels in Seropositive COVID-19 Patients in Mazandaran, Iran: A Six-Month Investigation.","authors":"Seyed Abbas Mousavi, Faezeh Sadat Movahedi, Fatemeh Safari Hajikalai, Jamshid Yazdani Charati, Abolghasem Ajami, Seyed Mohsen Soleimani, Zainab Bandalizadeh, Saeed Kaviani Charati","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Forecasting the longevity of patients' immune stability could be the most effective approach to preventing illnesses. This study investigates immunoglobulin M (IgM) serum longevity, immunoglobulin G (IgG), and corresponding risk factors in the first phase seropositive patients in Mazandaran, Iran.</p><p><strong>Materials and methods: </strong>This descriptive cross-sectional study aimed to assess IgM and IgG serum levels in a cohort of 184 seropositive patients during six months. The data analysis involved various statistical methods including descriptive statistics, the chi-square test, independent and paired t-tests, and single and multivariate logistic regression.</p><p><strong>Results: </strong>A total of 103 (56%) patients lacked the necessary antibodies, whereas 81 (44%) remained seropositive. According to the results of multivariable logistic regression, patients with a travel history, hospital admissions, and end-stage renal disease (ESRD) had 3.24 (P=0.04), 12.63 (P=0.018), and 9.79 (P=0.001) times higher chances of stable seropositivity, respectively. The average IgG and IgM serum levels fell by 4.5 and 3 units, respectively (P<0.001). In addition, serum levels of IgM and IgG increased by 12% and 12.5%, respectively, and dropped by 75.5% in both serums. There was no increase in either serum level for any of the patients.</p><p><strong>Conclusion: </strong>The duration of immune serum stability in patients can significantly reduce disease mortality. The concurrent detection of IgM and IgG antibodies also assists in identifying the infectious stage.</p>","PeriodicalId":22247,"journal":{"name":"Tanaffos","volume":"23 2","pages":"183-188"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is Non-Invasive Ventilation a Good Choice in All Patients with Severe COVID-19? A Cohort Retrospective Study. 无创通气是所有重症COVID-19患者的好选择吗?队列回顾性研究。
Q3 Medicine Pub Date : 2024-02-01
Ramin Sami, Babak Amra, Forogh Soltaninejad, Zohre Naderi, Marjan Mansourian, Mina Nickpour, Media Babahajiani, Marzieh Hashemi

Background: The recent outbreak of Coronavirus 2019 (COVID-19) is a respiratory disorder caused by the Acute Respiratory Syndrome Coronavirus 2. At the start of the epidemic, early intubation was the optimal strategy for managing ARDS caused by COVID-19. Several non-invasive methods for respiratory support in patients with moderate to severe COVID-19 may reduce intubation, disease severity, ventilator use, and hospitalization in the intensive care unit (ICU). In this study, the characteristics of COVID-19 patients who failed NIV therapy were compared with those who had successful NIV.

Materials and methods: The present descriptive-analytical study was conducted at the COVID-19 center of KHORSHID University Hospital. Patients were aged > 18 years with confirmed COVID-19 and hospitalized in the ICU from the beginning of January to the end of March 2021. They had an oxygen level of < 88% despite receiving 15 L of oxygen with reserve masks and were undergoing non-invasive ventilation (NIV) treatment. Data collection included patients' demographic information, vital signs, and test results upon hospital admission, and assessed disease severity using APACHE, SAPS, and SOFA scores. Patients were categorized into responders (R) and non-responders (NR) to determine predictors of non-invasive ventilation (NIV) success, with follow-up based on device tolerance and changes in vital signs.

Results: 71 Individuals were candidates for NIV. Twenty patients were excluded from the study, and 51 patients were included in the study. Of these, 35 patients underwent NIV treatment failure (NR). On the other hand, 16 (31.4%) patients completely recovered after receiving NIV (R) and they were discharged from the ICU.

Conclusion: Serum Albumin and BMI levels of COVID-19 patients undergoing NIV therapy seem to affect their responses to treatment. Hence, it is recommended to evaluate the nutritional status of patients before the start of NIV .

背景:最近爆发的2019冠状病毒(COVID-19)是由急性呼吸综合征冠状病毒2引起的呼吸系统疾病。在疫情开始时,早期插管是管理COVID-19引起的急性呼吸窘迫综合征的最佳策略。几种对中重度COVID-19患者进行呼吸支持的非侵入性方法可以减少插管、疾病严重程度、呼吸机使用和在重症监护病房(ICU)的住院时间。本研究比较了NIV治疗失败和成功的COVID-19患者的特征。材料和方法:本描述性分析研究在霍尔什德大学医院COVID-19中心进行。患者年龄为18岁,确诊为COVID-19,于2021年1月初至3月底在ICU住院。尽管他们接受了15l的氧气储备面罩,并接受了无创通气(NIV)治疗,但他们的血氧水平仍< 88%。数据收集包括患者的人口统计信息、生命体征和入院时的检查结果,并使用APACHE、SAPS和SOFA评分评估疾病严重程度。将患者分为反应者(R)和无反应者(NR),以确定无创通气(NIV)成功的预测因素,并根据设备耐受性和生命体征变化进行随访。结果:71例NIV候选病例。本研究排除20例患者,纳入51例患者。其中,35例患者出现NIV治疗失败(NR)。另一方面,16例(31.4%)患者在接受NIV (R)治疗后完全康复并出院。结论:接受NIV治疗的COVID-19患者血清白蛋白和BMI水平似乎影响其对治疗的反应。因此,建议在NIV开始前评估患者的营养状况。
{"title":"Is Non-Invasive Ventilation a Good Choice in All Patients with Severe COVID-19? A Cohort Retrospective Study.","authors":"Ramin Sami, Babak Amra, Forogh Soltaninejad, Zohre Naderi, Marjan Mansourian, Mina Nickpour, Media Babahajiani, Marzieh Hashemi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>The recent outbreak of Coronavirus 2019 (COVID-19) is a respiratory disorder caused by the Acute Respiratory Syndrome Coronavirus 2. At the start of the epidemic, early intubation was the optimal strategy for managing ARDS caused by COVID-19. Several non-invasive methods for respiratory support in patients with moderate to severe COVID-19 may reduce intubation, disease severity, ventilator use, and hospitalization in the intensive care unit (ICU). In this study, the characteristics of COVID-19 patients who failed NIV therapy were compared with those who had successful NIV.</p><p><strong>Materials and methods: </strong>The present descriptive-analytical study was conducted at the COVID-19 center of KHORSHID University Hospital. Patients were aged > 18 years with confirmed COVID-19 and hospitalized in the ICU from the beginning of January to the end of March 2021. They had an oxygen level of < 88% despite receiving 15 L of oxygen with reserve masks and were undergoing non-invasive ventilation (NIV) treatment. Data collection included patients' demographic information, vital signs, and test results upon hospital admission, and assessed disease severity using APACHE, SAPS, and SOFA scores. Patients were categorized into responders (R) and non-responders (NR) to determine predictors of non-invasive ventilation (NIV) success, with follow-up based on device tolerance and changes in vital signs.</p><p><strong>Results: </strong>71 Individuals were candidates for NIV. Twenty patients were excluded from the study, and 51 patients were included in the study. Of these, 35 patients underwent NIV treatment failure (NR). On the other hand, 16 (31.4%) patients completely recovered after receiving NIV (R) and they were discharged from the ICU.</p><p><strong>Conclusion: </strong>Serum Albumin and BMI levels of COVID-19 patients undergoing NIV therapy seem to affect their responses to treatment. Hence, it is recommended to evaluate the nutritional status of patients before the start of NIV .</p>","PeriodicalId":22247,"journal":{"name":"Tanaffos","volume":"23 2","pages":"176-182"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Hyssop (Hyssopus officinalis) Syrup on Mild to Moderate Asthma: A Randomized Double-Blind Placebo-Controlled Trial. 牛膝草糖浆治疗轻中度哮喘的疗效:一项随机双盲安慰剂对照试验。
Q3 Medicine Pub Date : 2024-02-01
Babak Daneshfard, Fatemeh Amini, Amir Mohammad Jaladat, Behrouz Momeni, Ali Abdolahinia, Ayda Hosseinkhani, Leila Hosseini

Background: Asthma is one of the most common respiratory diseases. Hyssopus officinalis L. is a medicinal herb that has shown anti-asthmatic effects and has also been recommended in Persian Medicine literature for its treatment. In this study, the efficacy of hyssop in mild to moderate asthma was investigated considering the patients' phenotype (having productive/non-productive cough).

Materials and methods: In a randomized triple-blind placebo-controlled trial, 60 mild-to-moderate asthmatic patients were randomized to receive either hyssop syrup (5 ml twice daily containing 6g Hyssopus officinalis L. extract) or plain sugar syrup (5 ml twice daily) for 4 weeks as an adjuvant to routine treatment. Outcome measures were the Asthma Control Test (ACT), pulmonary function tests, Expert Panel Report 3 (EPR3), and wheezing severity.

Results: The patients with productive cough in the hyssop group showed significant improvement in forced expiratory volume in 1 second (FEV1), ACT (at the 4th week), peak expiratory flow (PEF), maximal expiratory flow rate 25-75 (MEF25-75%), and wheezing severity. However, those with dry cough got worse regarding these indices.

Conclusion: Hyssop syrup is effective for asthmatic patients with productive cough and a higher BMI, but it is not suitable for those experiencing a dry cough. It highlights the importance of syndrome differentiation in asthmatic patients and a posteriori subgrouping in data analysis. This approach enhances treatment accuracy and response rates while reducing adverse effects. Future trials are guaranteed to approve this categorization in asthma treatment.

背景:哮喘是最常见的呼吸系统疾病之一。牛膝草(Hyssopus officinalis L.)是一种具有抗哮喘作用的草药,在波斯医学文献中也被推荐用于治疗。在本研究中,考虑到患者的表型(生产性咳嗽/非生产性咳嗽),研究了牛膝草对轻中度哮喘的疗效。材料和方法:在一项随机三盲安慰剂对照试验中,60名轻中度哮喘患者随机接受牛膝草糖浆(5ml,每日2次,含6g牛膝草提取物)或普通糖浆(5ml,每日2次)作为常规治疗的辅助治疗,为期4周。结果测量为哮喘控制测试(ACT)、肺功能测试、专家小组报告3 (EPR3)和喘息严重程度。结果:牛膝草组产咳患者1秒用力呼气量(FEV1)、ACT(第4周)、呼气峰流量(PEF)、最大呼气流速25-75 (MEF25-75%)、喘息严重程度均有显著改善。而干咳患者在这些指标上表现更差。结论:牛膝草糖浆对有咳痰、BMI较高的哮喘患者有效,但不适用于干咳患者。它强调了哮喘患者辨证的重要性和数据分析中的后验亚组。这种方法提高了治疗的准确性和有效率,同时减少了不良反应。未来的试验保证在哮喘治疗中批准这种分类。
{"title":"Effect of Hyssop (<i>Hyssopus officinalis</i>) Syrup on Mild to Moderate Asthma: A Randomized Double-Blind Placebo-Controlled Trial.","authors":"Babak Daneshfard, Fatemeh Amini, Amir Mohammad Jaladat, Behrouz Momeni, Ali Abdolahinia, Ayda Hosseinkhani, Leila Hosseini","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Asthma is one of the most common respiratory diseases. <i>Hyssopus officinalis</i> L. is a medicinal herb that has shown anti-asthmatic effects and has also been recommended in Persian Medicine literature for its treatment. In this study, the efficacy of hyssop in mild to moderate asthma was investigated considering the patients' phenotype (having productive/non-productive cough).</p><p><strong>Materials and methods: </strong>In a randomized triple-blind placebo-controlled trial, 60 mild-to-moderate asthmatic patients were randomized to receive either hyssop syrup (5 ml twice daily containing 6g <i>Hyssopus officinalis</i> L. extract) or plain sugar syrup (5 ml twice daily) for 4 weeks as an adjuvant to routine treatment. Outcome measures were the Asthma Control Test (ACT), pulmonary function tests, Expert Panel Report 3 (EPR3), and wheezing severity.</p><p><strong>Results: </strong>The patients with productive cough in the hyssop group showed significant improvement in forced expiratory volume in 1 second (FEV1), ACT (at the 4th week), peak expiratory flow (PEF), maximal expiratory flow rate 25-75 (MEF25-75%), and wheezing severity. However, those with dry cough got worse regarding these indices.</p><p><strong>Conclusion: </strong>Hyssop syrup is effective for asthmatic patients with productive cough and a higher BMI, but it is not suitable for those experiencing a dry cough. It highlights the importance of syndrome differentiation in asthmatic patients and a posteriori subgrouping in data analysis. This approach enhances treatment accuracy and response rates while reducing adverse effects. Future trials are guaranteed to approve this categorization in asthma treatment.</p>","PeriodicalId":22247,"journal":{"name":"Tanaffos","volume":"23 2","pages":"146-155"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Side Effects of COVID-19 Vaccination Following First and Second Doses: A Cross-Sectional Survey Based on Vaccine-associated Factors. 第一次和第二次接种COVID-19疫苗的副作用:基于疫苗相关因素的横断面调查
Q3 Medicine Pub Date : 2024-02-01
Sajjad Tavakkoli, Mohammad Rostami Nejad, Mohamad Amin Pourhoseingholi, Golshan Mirmomeni, Fatemeh Ghorbani, Mostafa Rezaei Tavirani, Somayeh Jahani-Sherafat, Mohammad Ali EmamHadi, Shahriar Janbazi, Alireza Zali, Mitra Rezaei, Reza M Robati

Background: Due to the rapid launch and development of vaccines (the most ideal protocol for countering COVID-19), monitoring of post-vaccination side effects is essential. This study aimed to assess symptoms and side effects of three types of COVID-19 vaccines (Sputnik, AstraZeneca, and Sinopharm) and the details of their relationship with demographic characteristics in Iran.

Materials and methods: A cross-sectional and telephonic interview-based study was conducted from May 12 to July 11, 2021, among 420 university staff who received both doses of the COVID-19 vaccine. The association of vaccination behavior-related symptoms after the first and second doses with age, gender, vaccine type, blood type, underlying medical situation, and past infection and reinfection with SARS-CoV-2 was analyzed.

Results: The majority of participants were men (58.7%), the median age was 41.30+11.208 years, and 18.6% were vaccinated with the Sputnik vaccine, 75.1% with Sinopharm, and 6.3% with AstraZeneca. In addition, 47.3% and 41.8% were symptomatic after first and second dose vaccination, respectively. The frequency of symptoms was higher in younger individuals, women, and AstraZeneca recipients (p = 0.001). The most frequently reported symptoms were fever, weakness, and muscular and injection site pain. These symptoms were more reported after the first dose than the second one. There was no significant connection between blood types, underlying medical situations, past infection and reinfection with SARS-CoV-2, and the prevalence of symptoms.

Conclusion: AstraZeneca, Sputnik, and Sinopharm COVID-19 vaccines were found to be safe and the lowest incidence of symptoms was seen in Sinopharm recipients.

背景:由于疫苗(抗击COVID-19最理想的方案)的快速推出和发展,监测疫苗接种后副作用至关重要。本研究旨在评估三种COVID-19疫苗(Sputnik、AstraZeneca和Sinopharm)的症状和副作用,以及它们与伊朗人口特征之间的关系。材料与方法:于2021年5月12日至7月11日对420名接种了两剂新冠肺炎疫苗的大学工作人员进行了横断面和电话访谈研究。分析第一次和第二次接种后接种行为相关症状与年龄、性别、疫苗类型、血型、基础医疗状况、既往感染和再感染SARS-CoV-2的相关性。结果:参与者以男性为主(58.7%),中位年龄为41.30+11.208岁,接种Sputnik疫苗的比例为18.6%,国药75.1%,阿斯利康6.3%。第一次和第二次接种后出现症状的分别为47.3%和41.8%。年轻个体、女性和阿斯利康接受者出现症状的频率更高(p = 0.001)。最常见的症状是发热、虚弱、肌肉和注射部位疼痛。这些症状在第一次服药后比第二次服药后报告的更多。血型、基础医疗情况、既往感染和再感染SARS-CoV-2与症状发生率之间无显著相关性。结论:阿斯利康、斯普特尼克和国药三种新型冠状病毒疫苗均为安全疫苗,且国药接种者的症状发生率最低。
{"title":"Side Effects of COVID-19 Vaccination Following First and Second Doses: A Cross-Sectional Survey Based on Vaccine-associated Factors.","authors":"Sajjad Tavakkoli, Mohammad Rostami Nejad, Mohamad Amin Pourhoseingholi, Golshan Mirmomeni, Fatemeh Ghorbani, Mostafa Rezaei Tavirani, Somayeh Jahani-Sherafat, Mohammad Ali EmamHadi, Shahriar Janbazi, Alireza Zali, Mitra Rezaei, Reza M Robati","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Due to the rapid launch and development of vaccines (the most ideal protocol for countering COVID-19), monitoring of post-vaccination side effects is essential. This study aimed to assess symptoms and side effects of three types of COVID-19 vaccines (Sputnik, AstraZeneca, and Sinopharm) and the details of their relationship with demographic characteristics in Iran.</p><p><strong>Materials and methods: </strong>A cross-sectional and telephonic interview-based study was conducted from May 12 to July 11, 2021, among 420 university staff who received both doses of the COVID-19 vaccine. The association of vaccination behavior-related symptoms after the first and second doses with age, gender, vaccine type, blood type, underlying medical situation, and past infection and reinfection with SARS-CoV-2 was analyzed.</p><p><strong>Results: </strong>The majority of participants were men (58.7%), the median age was 41.30+11.208 years, and 18.6% were vaccinated with the Sputnik vaccine, 75.1% with Sinopharm, and 6.3% with AstraZeneca. In addition, 47.3% and 41.8% were symptomatic after first and second dose vaccination, respectively. The frequency of symptoms was higher in younger individuals, women, and AstraZeneca recipients (p = 0.001). The most frequently reported symptoms were fever, weakness, and muscular and injection site pain. These symptoms were more reported after the first dose than the second one. There was no significant connection between blood types, underlying medical situations, past infection and reinfection with SARS-CoV-2, and the prevalence of symptoms.</p><p><strong>Conclusion: </strong>AstraZeneca, Sputnik, and Sinopharm COVID-19 vaccines were found to be safe and the lowest incidence of symptoms was seen in Sinopharm recipients.</p>","PeriodicalId":22247,"journal":{"name":"Tanaffos","volume":"23 2","pages":"115-128"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A 26-Year-Old Man with Productive Cough, Hemoptysis, and Weight Loss. 26岁男性,咳嗽咯血,体重减轻。
Q3 Medicine Pub Date : 2024-02-01
Faezeh Sharafi, Mitra Rezaei, Payam Tabarsi, Majid Marjani
{"title":"A 26-Year-Old Man with Productive Cough, Hemoptysis, and Weight Loss.","authors":"Faezeh Sharafi, Mitra Rezaei, Payam Tabarsi, Majid Marjani","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":22247,"journal":{"name":"Tanaffos","volume":"23 2","pages":"213-214"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Alarm for Pediatricians Facing BCG Vaccine Complications. 卡介苗并发症对儿科医生的警示
Q3 Medicine Pub Date : 2024-02-01
Shirin Sayyahfar, Abdoulreza Esteghamati, Nima Rezaei
{"title":"An Alarm for Pediatricians Facing BCG Vaccine Complications.","authors":"Shirin Sayyahfar, Abdoulreza Esteghamati, Nima Rezaei","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":22247,"journal":{"name":"Tanaffos","volume":"23 2","pages":"100-101"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Tanaffos
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1